Compare Banco Bilbao Vizcaya Argentaria SA (BBVA) vs HCA Health Inc (HCA) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Banco Bilbao Vizcaya Argentaria SA vs HCA Health Inc — how do they compare? Banco Bilbao Vizcaya Argentaria SA trades at $25.41 (market cap $142.30B), while HCA Health Inc trades at $372.59 (market cap $80.66B). The key difference: Banco Bilbao Vizcaya Argentaria SA is the larger of the two by market cap, and Banco Bilbao Vizcaya Argentaria SA pays the higher dividend (4.2%). Which is the better fit depends on your goals.
| BBVA | HCA | |
|---|---|---|
Market Cap | $142.30B | $80.66B |
Sector | Financials | Health |
52-Week High | $26.14 | $545.13 |
52-Week Low | $14.73 | $334.32 |
Dividend Yield | 4.2% | 0.86% |
Enterprise Value | — | $129.57B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
BBVA trades at $25.39, down 1.17% on the day, with a bullish technical signal from moving averages and strong fundamental metrics including a 26.51% net income margin and 18.67% ROE. Recent earnings beat expectations in Q1 2026, and revenue has grown steadily from $28.2B in 2022 to $39.4B in 2025. Positive analyst sentiment is reflected in a 53.85% buy rating, though legal and regulatory risks from ongoing probes in Spain present headwinds.
The outlook for BBVA remains positive given robust profitability and analyst support, but investors should weigh the stock's attractive valuation against litigation risks and sector volatility. Upside potential exists if earnings continue to exceed forecasts, but legal developments could pressure the share price near-term.
HCA Healthcare stock trades at $390.74, down 3.9% following a lowered 2026 profit outlook. The company maintains strong fundamentals with revenue growth to $75.6B in 2025 and consistent earnings beats, though technical indicators show bearish momentum. Recent news highlights challenges from payer mix shifts and rising uninsured patients, creating near-term headwinds despite long-term capacity expansion initiatives.
The stock presents a valuation opportunity with a P/E of 13.5x below industry averages, supported by analyst consensus target of $481.80. Key risks include execution on guidance and healthcare reimbursement pressures, but institutional sentiment remains positive with 63% buy ratings, suggesting potential recovery once near-term uncertainties resolve.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Banco Bilbao Vizcaya Argentaria SA
Despite its Spanish origins, BBVA generates three quarters of its profits in emerging markets, especially Mexico that contributes nearly half of BBVA's net profit. BBVA is overwhelmingly a retail and commercial bank with corporate and investment banking forming a smaller part of the overall business.
Read more on BBVA →About HCA Health Inc
HCA Healthcare is a Nashville-based healthcare provider organization operating the largest collection of acute-care hospitals in the U.S. As of December 2021, the firm owned and operated 182 hospitals, 125 freestanding outpatient surgery centers, and a broad network of physician offices, urgent care clinics, and freestanding emergency rooms across nearly 20 states and a small foothold in England.
Read more on HCA →
